These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8527015)

  • 21. [Pharmacoepidemiolgy: regulatory basis, methodological approaches and scope].
    Ahid S; Belaguide K; Cherrah Y
    East Mediterr Health J; 2012 Jan; 18(1):85-93. PubMed ID: 22360016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Keeping the Pharmacology in Pharmacoepidemiology.
    Staffa JA
    Clin Pharmacol Ther; 2021 Jun; 109(6):1393-1394. PubMed ID: 32827442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
    Hilmer SN; Gnjidic D; Abernethy DR
    J Gerontol A Biol Sci Med Sci; 2012 Feb; 67(2):181-8. PubMed ID: 21653991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International data standards for hospital-based drug surveillance.
    Kurata JH; Overhage M; Gabrieli E; Jones JK
    MD Comput; 1995; 12(1):50-7. PubMed ID: 7854080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Issues related to monitoring the safety of over-the-counter (OTC) medicines.
    Bond C; Hannaford P
    Drug Saf; 2003; 26(15):1065-74. PubMed ID: 14640771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases.
    Berdaï D; Thomas-Delecourt F; Szwarcensztein K; d'Andon A; Collignon C; Comet D; Déal C; Dervaux B; Gaudin AF; Lamarque-Garnier V; Lechat P; Marque S; Maugendre P; Méchin H; Moore N; Nachbaur G; Robain M; Roussel C; Tanti A; Thiessard F
    Therapie; 2018 Feb; 73(1):13-24. PubMed ID: 29530314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Future Perspective of Pharmacoepidemiology in the "Big Data Era" and the Growth of Information Sources].
    Macías Saint-Gerons D; de la Fuente Honrubia C; de Andrés Trelles F; Catalá-López F
    Rev Esp Salud Publica; 2016 Dec; 90():e1-e7. PubMed ID: 27905352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

  • 29. Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist.
    Radawski C; Morrato E; Hornbuckle K; Bahri P; Smith M; Juhaeri J; Mol P; Levitan B; Huang HY; Coplan P; Li H;
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1233-40. PubMed ID: 26456379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?
    Briggs AH; Levy AR
    Pharmacoeconomics; 2006; 24(11):1079-86. PubMed ID: 17067193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacoepidemiology of COPD: recent advances and methodological discussion.
    Burney P; Suissa S; Soriano JB; Vollmer WM; Viegi G; Sullivan SD; Fabbri LM; Sin DD; Ernst P; Coultas D; Bourbeau J; Mapel DW; Weiss K; McLaughlin T; Price D; Sturkenboom MC; Taylor R; Hagan GW
    Eur Respir J Suppl; 2003 Sep; 43():1s-44s. PubMed ID: 14582902
    [No Abstract]   [Full Text] [Related]  

  • 33. The promise of pharmacoepidemiology in helping clinicians assess drug risk.
    Avorn J
    Circulation; 2013 Aug; 128(7):745-8. PubMed ID: 23940388
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmaco-epidemiology and -economics should be developed more extensively in veterinary medicine.
    Chauvin C; Madec F; Guittet M; Sanders P
    J Vet Pharmacol Ther; 2002 Dec; 25(6):455-9. PubMed ID: 12485351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 36. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies.
    Palmaro A; Moulis G; Despas F; Dupouy J; Lapeyre-Mestre M
    Fundam Clin Pharmacol; 2016 Dec; 30(6):616-624. PubMed ID: 27351637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
    Shakir SA; Layton D
    Drug Saf; 2002; 25(6):467-71. PubMed ID: 12071785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developments in post-marketing comparative effectiveness research.
    Schneeweiss S
    Clin Pharmacol Ther; 2007 Aug; 82(2):143-56. PubMed ID: 17554243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Developing process of guide on methodological standards in pharmacoepidemiology (T/CPHARMA 002-2019)].
    Xu Y; Ding CY; Zhuo L; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Oct; 40(10):1186-1190. PubMed ID: 31658514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoepidemiology: the industry's perspective.
    Tilson HH
    J Rheumatol Suppl; 1988 Oct; 17():28-33. PubMed ID: 3204617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.